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Abstract 
Background: Beta-2-microglobulin (B2M), a light chain subunit of the major histocompatibility complex (MHC) class 
I complex, has been implicated in tumorigenesis. However, whether it is expressed in different epithelial-type ovarian 
tumours remains unknown. This study was performed to examine the expression of B2M in different histopathological 
types of ovarian tumours, to explore the function of B2M in ovarian cancer (OC) cells and to investigate the mecha-
nisms underlying the regulation of B2M by the TGF-β signaling pathway.
Methods: B2M expression in normal ovarian tissues and epithelia-type ovarian tumours was detected by immuno-
histochemistry and Western blot, followed by the analysis of association with clinical features. OC cells were trans-
fected with B2M-siRNA and cell proliferation, migration and invasion were determined by WST-1 assay, wound healing 
assay and Transwell invasion assay, respectively. The regulation of B2M by the TGF-β signaling pathway in OC cells was 
examined by Western blot, ELISA and qRT-PCR.
Results: We found that B2M was overexpressed in ovarian borderline and malignant tumours compared with benign 
tumours and normal controls, but was not associated with age, tumour size, lymph node metastasis and clinical stage. 
Knocking down of B2M led to a decrease in OC cell proliferation, migration and invasion. The expression of B2M was 
downregulated by TGF-β1 in OC cells, which was abolished in the presence of the inhibitor of TGF-β type I receptor.
Conclusion: Our findings suggest that B2M is a potential tissue biomarker and therapeutic target of borderline and 
malignant ovarian tumours and the dysregulation of B2M in these tumours may be mediated by the TGF-β signaling 
pathway.
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Background
Beta-2-microglobulin (B2M), a light chain subunit of the 
major histocompatibility complex (MHC) class I com-
plex, is associated with the heavy chain (α-chain) of the 
complex on the surface of nearly all nucleated cells. It 
exists in two forms, membrane and soluble B2M, which 
freely exchange with each other [1–3]. A high level of 
soluble B2M is detected in several types of cancers, 
including breast [4], colorectal [5], gastric [6], lung [7], 
oral [8], ovarian [9], prostate [10] and testicular [11] can-
cers, and may be implicated in the immune escape of 
cancer cells and cancer immunotherapy [12–15]. Accu-
mulating data suggest that B2M may be a biomarker for 
cancers and a potential target for cancer therapy. The 
functional study of B2M in cancer cells has shown that 
B2M plays an important role in the promotion of cancer 
cell growth [16]. The growth-stimulatory activity of B2M 
may be associated with the antagonistic activity of B2M 
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TGF-β belongs to a superfamily of secreted cytokines 
and plays a pivotal role in immunosuppressive action. 
TGF-β signals through the activation of serine/threonine 
kinase receptors on the cell surface and their transducer 
proteins, Smads such as Smad2/3, in the cytosol [18, 19]. 
It has been shown that TGF-β signaling is dysregulated 
in several human diseases [20], including epithelial-type 
ovarian malignant tumour often referred to as epithelia 
ovarian cancer (EOC) which is the most lethal gyneco-
logical malignancy [21]. TGF-β modulates the invasion of 
ovarian cancer (OC) and affects the metastatic potential 
of OC cells [22–24]. Our previous study also shows that 
TGF-β1 can mediate a progression marker cystatin B in 
human epithelial-type ovarian tumours [25].
The present study was undertaken to examine the 
expression of B2M in human epithelial-type ovarian 
tumours, including benign, borderline and malignant 
tumours, and to investigate the biological function of 
B2M in OC cells. We further explore the mechanisms 
underlying the regulation of B2M by the TGF-β signaling 
pathway.
Methods
Patients and ovarian tissue sample preparation
All samples were obtained with informed consent from 
patients and the study on human subjects was approved 
by the Ethics Committee of Jinshan Hospital, Fudan Uni-
versity. A total of 148 paraffin-embedded ovarian samples 
were collected from patients (40 normal samples from 
patients with non-ovarian tumour and 108 epithelial-
type tumour samples, including 38 benign, 38 borderline 
and 32 malignant tumours) with median age 50  years 
(range 17–81 years) at Jinshan Hospital, Fudan University 
(Shanghai, China) between 2005 and 2014. All patients 
underwent cytoreductive surgery. None of the patients 
had received a chemotherapy or radiotherapy before sur-
gery. The 10 % formalin-fixed paraffin-embedded ovarian 
tissue specimens were prepared and pathologically diag-
nosed in the Department of Pathology. Four micrometer 
thick tissue of specimen was sectioned for the histologi-
cal examination and the immunohistochemical (IHC) 
assay.
Immunohistochemical staining and analysis
IHC analysis was performed as described previously [25]. 
Briefly, the sections were deparaffinized and rehydrated. 
After blocking with 10  % normal goat serum (Maixin 
Bio, Cat# SP KIT-B2, Fuzhou, Fujian, China) for 10 min 
at room temperature, the sections were incubated with 
a polyclonal rabbit anti-B2M antibody (1:1000 dilution, 
Abcam, Cat# ab15976, Cambridge, UK) at 4 °C overnight, 
followed by incubation with biotinylated anti-rabbit sec-
ondary antibody (Maixin Bio, Cat# KIT-9922) at room 
temperature for 1  h. After washing with PBS, the sig-
nal was detected using a DAB Kit (Maixin Bio). Finally, 
the sections were counterstained with hematoxylin and 
photographed under a light microscope (BX43, OLYM-
PUS, Tokyo, Japan). A brown color in epithelial cells was 
considered as positive staining. The evaluation of B2M 
immunoreactive staining was done by two independent 
pathologists without any prior knowledge of patient’s 
clinical data. The scoring system [25] was classified into 
B2M-positive and -negative groups. A normal ovarian 
tissue without a primary antibody was used as a negative 
control.
Protein extraction from frozen ovarian tissue
The fresh tissue of the ovaries from patients were imme-
diately immersed in liquid nitrogen after surgical resec-
tion and then stored at −80 °C until use. About 100 mg 
of tissue sample was lysed with 1  ml of ice-cold SDS 
lysis buffer (Beyotime, Haimen, Jiangsu, China) with 1 % 
PMSF (Beyotime) and 1  % phosphatase inhibitor (Key-
GEN, Nanjing, Jiangsu, China), followed by dissociation 
using homogenizer. After centrifugation at 3000 rpm for 
5 min, the supernatant was transferred to a new tube, fol-
lowed by sonication for 15 s. Samples were then centri-
fuged at 14,000 rpm for 15 min at 4 °C. The pellets were 
discarded and the concentration of protein in superna-
tant was measured by a BCA Protein Assay kit (Thermo 
Scientific, Rockford, IL, USA). Lysates were then stored 
at −80 °C until use.
Cell culture and TGF‑β treatment
Human OC cell lines, OVCAR-3 and SK-OV-3, were 
purchased from American Type Culture Collection 
(ATCC). Cells were cultured as described previously [25]. 
For TGF-β1 treatment, cells were seeded for 24  h and 
then treated with 10  ng/ml recombinant human TGF-
β1 (R&D Systems, Cat# 240-B, Minneapolis, MN, USA) 
for 24, 48 or 72  h. SB-431542, a TGF-β type I receptor 
kinase inhibitor, was obtained from Sigma (Cat# S4317-
5MG, Saint Louis, MO, USA) and dissolved at a concen-
tration of 10 mM in dimethyl sulfoxide (DMSO) (Sigma). 
For blocking the TGF-β signaling pathway, cells were 
pre-treated with 10 μM SB-431542 for 30 min and then 
treated with TGF-β1 for 48 or 72  h. Cells without any 
treatment were used as a control.
Small interfering RNA transfection
OVCAR-3 and SK-OV-3 cells were plated into 6-well 
plate at a density of 2  ×  105/well and 1.5  ×  105/well, 
respectively, for 24  h and then transfected with 2  μg/
well (OVCAR-3) or 1.5  μg/well (SK-OV-3) of human 
B2M-small interfering RNA (B2M-siRNA) or nonspecific 
scramble control siRNA (C-siRNA). The sequences of 
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human B2M-siRNA were 5′-CCAGCGUACUCCAAAG 
AUUTT-3′ (sense) and 5′-AAUCUUUGGAGUACGC 
UGGTT-3′ (antisense) and the sequences of C-siRNA 
were 5′-UUCUCCGAACGUGUCACGUTT-3′ (sense) 
and 5′-ACGUGACACGUUCGGAGAATT-3′ (anti-
sense) (synthesized by GenePharma, Shanghai, China). 
The siRNA was diluted in 100 μl serum-free Opti-MEM 
medium (Gibco, Cat# 31985-070, Thermo Fisher Sci-
entific), mixed with 10  μl (OVCAR-3) or 8  μl (SK-OV-
3) X-tremeGENE siRNA Transfection Reagent (Roche 
Diagnostics, Cat# 4476093001, Indianapolis, IN, USA) 
and incubated for 20  min at room temperature accord-
ing to the manufacturer’s instruction. After transfection 
for 6 h, the medium was removed and replaced with fresh 
RPMI-1640 (OVCAR-3) or DMEM (SK-OV-3) supple-
mented with 10  % FBS without antibiotics. Cells were 
further incubated for the experiments as indicated.
Cell proliferation assay
Cells were plated into a 96-well plate at a density of 4500/
well (OVCAR-3) or 3000/well (SK-OV-3) and transfected 
with 0.6 μg/well (OVCAR-3) or 0.5 μg/well (SK-OV-3) of 
human B2M-siRNA or C-siRNA, respectively, and incu-
bated for 24  h. Cell proliferation was measured using 
the Cell Proliferation Reagent (WST-1) kit (Roche, Cat# 
11644807001) according to the manufacturer’s instruc-
tion. The signal in OD was read at 450  nm by a plate 
reader (BioTek Epoch, Winooski, VT, USA). Experiment 
was repeated at least three times.
Wound healing assay
Cells were seeded into 6-well plates at a density of 3 × 105 
cells/well and cultured up to 85  % confluence. The cell 
monolayer was then scraped using a pipette tip to gener-
ate scratch wounds. After washing three times to remove 
cell debris, the cells were transfected with B2M-siRNA or 
C-siRNA and incubated for 24, 48 and 72 h. Images were 
obtained at different time points and the widths of the 
gaps were measured and analyzed.
Cell invasion assay
The Matrigel (250  µg/ml final concentration, BD Bio-
sciences, Cat# 356234, Bedford, MA, USA) was coated 
on the top chamber of Transwell (pore size 8  μm, Cos-
tar, Corning, Cat# 3422, New York, NY, USA) in a 
24-well plate. After the solidification of the Matrigel, 
B2M-siRNA-transfected or C-siRNA-transfected cells 
(1  ×  104 cells, 24-hour post-transfection) were plated 
in the top chamber of Transwell with 180 μl serum-free 
medium. The bottom chamber was supplemented with 
600 μl medium supplemented with 10 % FBS as a chemo-
attractant. After incubation at 37  °C for 48  h, the non-
invaded cells were removed from the upper chamber. 
The invaded cells that had passed through the Matrigel-
coated membrane and attached to the lower surface of 
the membrane were fixed with 4  % paraformaldehyde, 
stained with 5 % Crystal Violet Staining Solution (Beyo-
time, Cat# C0121) for visualization, and photographed 
with a camera. The cell number was counted in three 
random fields viewed by a light microscope. The tests 
were repeated at least three times.
RNA extraction and quantitative real time PCR
Total RNA in the cells was extracted using Trizol reagent 
(Invitrogen, Thermo Fisher Scientific, Rockford, IL, USA), 
according to the manufacturer’s instruction. Five-hun-
dred nanogram of total RNA was reversely transcribed 
using a reverse transcription kit (TaKaRa Biotechnol-
ogy Co., Ltd., Dalian, Liaoning, China). The primer 
sequences of human B2M were 5′-GGTTTCATCCAT 
CCGACATTG-3′ (forward) and 5′-CATGTCTCGATCCC 
ACTTAAC-3′ (reverse). The primer sequences of human 
β-actin were 5′-ACAATGTGGCCGAGGACTTT-3′ 
(forward) and 5′-GCACGAAGGCTCATCATTCA-3′ 
(reverse) (synthesized by Sangon Biotech Co., Ltd., 
Shanghai, China). PCR amplification was performed 
at 95  °C for 5  s and 60  °C for 30 s for 40 cycles using a 
SYBR Premix TaqTM II (Tli RNaseH Plus) kit (TaKaRa 
Biotechnology Co., Ltd.) with an initial step of denaturing 
RNA at 95  °C for 30 s. Assays were conducted in tripli-
cate and repeated at least three times. The amount of tar-
get (B2M) normalized to an endogenous control (β-actin) 
given by 2ΔΔCt, in which threshold cycle (Ct) was obtained 
using Sequence Detection Software v1.4 (7300 Real Time 
PCR System, Applied Biosystems, Foster City, CA, USA).
Western blotting
OVCAR-3 and SK-OV-3 cells were lysed in RIPA lysis 
buffer (Thermo Scientific, Rockford, USA) with 1  % 
PMSF (Beyotime) and 1  % phosphatase inhibitor (Key-
GEN), followed by sonication. The cell lysates were cen-
trifuged at 14,000 rpm for 15 min at 4 °C. Equal amount 
proteins were separated on 15 % SDS-PAGE with 4X Pro-
tein SDS PAGE Loading Buffer (TaKaRa) and transferred 
to a PVDF membrane (Millipore, Billerica, MA, USA). 
After blocking with 5  % non-fat milk in Tris-buffered 
saline with Tween 20 (TBS-T) for 1 h, the membrane was 
incubated with a primary antibody at 4 °C overnight and 
subsequently incubated with horseradish peroxidase-
conjugated goat anti-rabbit or anti-mouse IgG (1:10,000 
dilution, Cell Signaling Technology, Inc., Danvers, MA, 
USA) for 1 h at room temperature. The following primary 
antibodies were used: rabbit anti-B2M (1:3000 dilution, 
Abcam), mouse anti-Smad2 and rabbit anti-phospho-
Smad2 (both 1:2000 dilution, Cat# 3103 and #3101, 
Cell Signaling Technology, Inc.) and rabbit anti-β-actin 
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(1:5000 dilution, Cat# 66009-1-Ig, Proteintech, Wuhan, 
China). Signals were detected using Immobilon™ West-
ern Chemiluminescent HRP Substrate (Millipore) and 
quantified using Tanon-4500 Gel Imaging System with 
GIS ID Analysis Software v4.1.5 (Tanon Science and 
Technology Co., Ltd., Shanghai, China).
Enzyme‑linked immunosorbent assay
Cells were seeded into 6-well plates at a density of 
2  ×  105 cells/well (OVCAR-3) or 1.5  ×  105 cells/well 
(SK-OV-3) and cultured with complete medium for 
24  h. After washing with PBS, cells were incubated in 
serum-free medium without or with 10  ng/ml of TGF-
β1 for 24, 48 and 72 h. The culture media were collected 
and centrifuged at 2000 rpm for 10 min at 4 °C. The cell 
lysates were extracted as described previously in West-
ern blotting. Equal amount samples were subjected to 
the enzyme-linked immunosorbent assay (ELISA). The 
concentration of B2M in medium and cytosol was deter-
mined using a Human B2M ELISA Kit (RayBiotech, Cat# 
ELH-B2M, Norcross, GA, USA) according to the manu-
facturer’s instruction. Briefly, 100 µl standards and sam-
ples were respectively added into the wells and incubated 
at 4 °C overnight. After washing away any unbound sub-
stance, 100 µl biotinylated anti-Human B2M was added 
into each well and incubated at room temperature for 
1 h. After washing, 100 µl HRP-Streptavidin solution was 
added to each well and incubated at room temperature 
for 45 min. After another washing, 100 µl TMB One-Step 
Substrate Reagent was added into each well and incu-
bated at room temperature in the dark for 20 min. After 
adding 50  µl Stop Solution into each well, the signal in 
OD was determined at 450 nm using a microplate reader 
immediately (BioTek Epoch).
Statistical analyses
All analyses were performed with SPSS Statistics 21 for 
Windows (SPSS, Chicago, IL, USA). For comparison 
between two groups of positivity and the association of 
B2M protein expression with histological types or the 
clinicopathological characteristics, Chi square test or 
Fisher’s exact test was applied. For comparison between 
two groups in treatment experiment, two-sample Wil-
coxon rank-sum test was used. Results are presented 
as the mean  ±  standard error of mean (SEM). A P 
value <0.05 was considered to be significant.
Results
B2M expression in the epithelial‑type tumours of the ovary
To examine the expression of B2M in ovarian tissue 
derived from patients with or without ovarian tumour, 
IHC staining and Western blot were applied. We found 
that the immunoreactive staining of B2M was observed 
in ovarian epithelial cells (Fig.  1a). The high staining of 
B2M was shown in borderline and malignant tumours, 
including serous, mucinous, endometrioid and clear cell 
tumours. The case rate of positive expression was signifi-
cantly increased in patients with benign, borderline, and 
malignant tumours compared to patients without ovar-
ian tumours (normal vs. benign, P  =  0.041; normal vs. 
borderline, P  <  0.001; normal vs. malignant, P =  0.001; 
benign vs. borderline, P  =  0.073; benign vs. malignant, 
P = 0.173; borderline vs. malignant, P = 0.719) (Fig. 1b). 
Western blot analysis showed that the expression of B2M 
was significant higher in the serous borderline and malig-
nant tumours of the ovary (Fig. 1c, d).
Association of B2M expression with the clinicopathological 
features of patients with ovarian tumours
Next we examined whether the expression of B2M is asso-
ciated with the clinicopathological features of patients with 
epithelial-type ovarian tumours. We observed that the 
expression of B2M was not associated with the age at the 
time of diagnosis and with primary tumour size (Table 1). 
By multiple comparisons of B2M protein expression asso-
ciated with histopathological characteristics, we found 
that the positivity of B2M expression was not significantly 
different between various histological types in benign, bor-
derline and malignant tumours (P  >  0.05). There was no 
significant difference between high-grade and low-grade 
serous malignant tumours (P = 0.83). Further analysis of 
patients with EOC showed that the expression of B2M had 
no association with clinicopathological features, such as 
age (≤45 vs. >45), tumour size (≤2 cm vs. >2 cm), multi-
focal tumours, lymph node metastasis, and clinical stages 
(Table 2) (all P > 0.05).
Effect of knocking down of B2M on ovarian cancer cell 
proliferation, migration and invasion
To determine the functional effects of B2M on the bio-
logical behaviors of OC cells, a loss-of-function approach 
was applied. First, several siRNAs specific to human B2M 
(B2M-siRNA) were synthesized. Second, transfection 
efficiency was tested prior to full experiments. Reduc-
tion of B2M protein was confirmed in two EOC cell 
lines, OVCAR-3 and SK-OV-3, by Western blot (Fig. 2a, 
b). Next we examined cell proliferation by WST-1 assay. 
The inhibition of B2M expression by B2M-siRNA signifi-
cantly decreased OVCAR-3 and SK-OV-3 cell prolifera-
tion at 48 h post-transfection (Fig. 2c, d; n = 3; P < 0.01).
To evaluate the effect of B2M on OC cell migration, a 
wound-healing assay was performed in SK-OV-3 cells. 
As shown in Fig. 3a, b, the suppression of B2M expres-
sion significantly inhibited SK-OV-3 cell migration com-
pared with the blank and negative control (C-siR) (n = 3; 
P < 0.05).
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Fig. 1 B2M protein expression in human ovarian tissues. a Immunohistochemical staining of B2M protein in human epithelia-type ovarian tumours. 
A brown color in epithelial cells is considered as a positive staining. Negative control without first antibody is performed in the normal ovarian tissue. 
Representative images of B2M expression in serous, mucinous, endometrioid and clear cell tumours and the normal ovarian tissue are shown. Origi-
nal magnification × 100 and × 400. Scale bar 100 µm. b The case rate of B2M positive and negative. Positive vs. negative: 16/24 in control without 
tumour (40 cases), 24/14 in benign tumour (38 cases), 31/7 in borderline tumour (38 cases) and 25/7 in malignant tumour (32 cases). For compari-
son between two groups, χ2 test was applied. c Detection of B2M expression in the normal ovarian tissues (case #1–3) and serous benign (case 
#4–6), borderline (case #7–9) and malignant (case # 10–12) tumours by Western blot. d Semi-quantitative analysis after densitometry on the gels of 
(c). Benign, benign tumour; Borderline, borderline tumour; Malignant, malignant tumour; Normal, normal ovarian tissue. *P < 0.05; **P < 0.01
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Next we examined the effect of B2M on cell invasion in 
SK-OV-3 cells. After culture for 48  h, the non-invading 
cells at the upper layer of chamber were removed and the 
number of invading cells at the low layer was counted. 
We found that the suppression of B2M expression signifi-
cantly inhibited SK-OV-3 cell invasion by approximately 
65 % (Fig. 3c, d; n = 3; P < 0.05).
Regulation of B2M expression by the TGF‑β signaling 
pathway in ovarian cancer cells
Since TGF-β signaling pathway plays a significant role 
in ovarian tumorigenesis and B2M was associated with 
the biological behaviour of OC, we subsequently inves-
tigated whether the TGF-β signaling pathway mediates 
B2M expression. OVCAR-3 and SK-OV-3 cells were 
treated with TGF-β1 (10  ng/ml) for 24, 48 and 72  h, 
respectively. By Western blot analysis we observed that 
B2M expression, after normalized to β-actin, was sig-
nificantly decreased after TGF-β1 treatment at 72  h in 
OVCAR-3 cells (Fig.  4a, c; P  <  0.05). We also found a 
decrease of B2M expression in SK-OV-3 after TGF-β1 
treatment for 24 and 48 h (Fig. 4b, d; P < 0.05). Because 
Smad2 is a TGF-β signaling transducer protein and is 
activated upon TGF-β1 treatment, we subsequently 
detected the phosphorylation of Smad2 to see if these 
cells respond to TGF-β1. Indeed, an increase of Smad2 
phosphorylation was observed in TGF-β1 treated 
OVCAR-3 (Fig.  4e) and SK-OV-3 (Fig.  4f ) cells, indi-
cating that the TGF-β signaling pathway exists in those 
cells.
Table 1 Association of  B2M expression with  the clinico- 
and histo-pathological features of patients with epithelial-
type ovarian tumours
The expression of B2M protein was detected by immunohistochemistry. For 
comparison of B2M expression associated with age, χ2  test was applied. For 
comparison of B2M expression associated with primary tumour size, χ2 test with 
continuity correction was applied. For multiple comparisons of B2M expression 
associated with the histopathological features, Fisher’s exact test was applied
n number of cases; Positive positive expression; Negative negative expression
a Multiple comparisons of the histological types (serous, mucinous and 
endometrioid tumours) in benign tumors
b Comparison between serous and mucinous borderline tumours
c Multiple comparisons of the histological types (serous, mucinous and clear cell 
tumours) in malignant tumors




n B2M expression P value
Positive n (%) Negative n (%)
Age at diagnosis
 ≤45 41 32 (78.05) 9 (21.95) 0.567
 >45 67 49 (73.13) 18 (26.87)
Primary tumour size
 ≤2 cm 7 6 (85.71) 1 (14.29) 0.498
 >2 cm 101 75 (74.26) 26 (25.74)
Benign tumour
 Serous 16 12 (68.75) 4 (31.25) 0.326a
 Mucinous 18 9 (88.24) 9 (11.76)
 Endometrioid 4 2 (50.00) 2 50.00)
Borderline tumour
 Serous 14 10 (71.43) 4 (28.57) 0.191b
 Mucinous 21 19 (90.48) 2 (9.52)
 Clear cell 1 1 (100) 0
 Endometrioid 1 1 (100) 0
 Transitional cell 1 1 (100) 0
Malignant tumour >0.999c
 Serous
  High-grade 12 11 (91.67) 1 (8.33) 0.083d
  Low-grade 6 3 (50.00) 3 (50.00)
 Mucinous 5 4 (80.00) 1 (20.00)
 Clear cell 7 5 (71.43) 2 (28.57)
 Endometrioid 1 1 (100) 0
 Transitional cell 1 1 (100) 0
Table 2 Association of  B2M expression with  the clinico-
pathological features of patients with EOC
The expression of B2M proteins was detected by immunohistochemistry. 
For comparison of B2M expression associated with age, primary tumour size, 
multifocal, LN metastasis, and clinical stages, Fisher’s exact test was applied
EOC epithelial ovarian cancer; n number of cases; Positive positive expression; 
Negative negative expression; LN lymph node
Clinicopathological 
features
n B2M expression P value
Positive (%) Negative (%)
Age at diagnosis
 ≤45 8 6 (75.00) 2 (25.00) >0.999
 >45 24 19 (79.17) 5 (20.83)
Primary tumour size
 ≤2 cm 4 4 (100.00) 0 (0.00) 0.552
 >2 cm 28 21 (75.00) 7 (25.00)
Multifocal tumours
 Yes 15 13 (86.67) 2 (13.33) 0.402
 No 17 12 (70.59) 5 (29.41)
LN metastasis
 Yes 4 3 (75.00) 1 (25.00) >0.999
 No 28 22 (78.57) 6 (21.43)
FIGO stage
 I 17 12 (70.59) 5 (29.41) 0.207
 II 7 5 (71.43) 2 (28.57)
 III 8 8 (100.00) 0 (0.00)
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The suppression of B2M by TGF-β1 was further con-
firmed by an ELISA assay. We found that TGF-β1 (10 ng/
ml) significantly decreased cytosolic B2M in OVCAR-3 
cells after 72 h treatment and in SK-OV-3 cells after 24 
and 48 h treatment, respectively, but the concentration of 
B2M in the culture medium was not affected (Fig. 5a, b).
Next, we blocked the TGF-β signaling pathway by the 
inhibitor of TGF-β type I receptor kinases, SB-431542, to 
evaluate whether the B2M expression is mediated by the 
TGF-β signaling pathway. By comparing with the vehicle 
control group, we found that TGF-β1 had an inhibitory 
effect on the expression of B2M. The expression of B2M 
mRNA was significantly decreased after 10 ng/ml TGF-
β1 treatment for 24 h in OVCAR-3 (Fig. 6a) and SK-OV-3 
(Fig.  6b) cells detected by quantitative RT-PCR (both 
P  <  0.05). This downregulation of B2M mRNA expres-
sion by TGF-β1 was attenuated in the cells pre-treated 














































































Fig. 2 Measurement of cell proliferation. Transfection efficiency in OVCAR-3 (a) and SK-OV-3 (b) cells. A knocking down of B2M was detected by 
Western blot (top panel), followed by the densitometry of the gel (n = 3). The cell proliferation of OVCAR-3 (c) and SK-OV-3 (d) was determined by 
the WST-1 assay after siRNA transfection (n = 3). The results are representative of three independent experiments. Blank, control without transfec-
tion; C-siR, control siRNA; B2M-siR, B2M-siRNA. **P < 0.01
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expression was also observed at the protein level detected 
by Western blot. We found that the expression of B2M 
protein was significantly decreased in OVCAR-3 (Fig. 6c) 
and SK-OV-3 (Fig. 6d) cells after 10 ng/ml TGF-β1 treat-
ment for 72 and 48  h, respectively, and the decrease 
of B2M by TGF-β1 was abolished in the presence of 
SB-431542 (P < 0.05). These data indicate that the expres-
sion of B2M is regulated by the TGF-β signaling pathway.
Discussion
The current study showed the overexpression of B2M 
in human epithelial-type borderline and malignant 
tumours and evaluated the expression of B2M associated 
with clinicopathological features in patients with EOC. 
Using a loss-of-function approach, the biological func-
tion of B2M in OC cells was examined. Furthermore, we 
explored for the first time the regulation of B2M expres-
sion at mRNA and protein levels by the TGF-β signaling 
pathway in OC cells.
B2M is a component of the MHC class I complex asso-
ciated with the α-chain of the complex to regulate the 
immune system in human. It has been shown that B2M 
is a biomarker of inflammation, while the inflammation 
is associated with cancers. Indeed, more and more evi-
dences provide the information that B2M plays a role in 
cancer biology. Clinical studies suggest that soluble B2M 
is a serum marker of the several types of cancers, includ-



















































Fig. 3 Migration and invasion of SK-OV-3 cells. a Migration of SK-OV-3 after transfection. A wound healing assay was performed and compared 
between the blank, negative control and B2M-siRNA transfected cells. The photos of wounds were taken at different times. Original magnifica-
tion × 100. b The quantitative analysis of the wound width was shown in the line chart. Three independent experiments were conducted and 
similar results were obtained. c Invasion of SK-OV-3 after transfection. The invasive property of the cells was determined at 48 h by invasion assays 
using Matrigel invasion chambers and the photos were taken. Original magnification × 200. d Quantification of invading cells. The results are plot-
ted as the average number of invading cells from three random microscopic fields. Three independent experiments were performed and similar 
results were obtained. *P < 0.05
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found in 56  % OC patients [9]. Recently, an increase of 
B2M concentration is also detected in saliva [26] and 
peritoneal fluid [27] of patients with OC. Data min-
ing of NCBI GEO DataSets showed that B2M mRNA 
was expressed in OC epithelial cells as well as in ovar-
ian normal surface epithelia cells in the study of gene 
expression profiling analyses [28]. However, the expres-
sion of B2M in the different types of ovarian tumours 
is barely reported. Current study examined for the first 
time the expression of B2M in human different epithelial-
type ovarian tumours compared with the normal ovary. 
The positivity of B2M expression was higher in patients 











































































Fig. 4 Effect of TGF-β1 on the expression of B2M protein in ovarian cancer cell lines. In a time-course study, OVCAR-3 (a) and SK-OV-3 (b) cells were 
treated with 10 ng/ml of TGF-β1 for 24, 48 and 72 h, respectively. Equal amounts of total protein were subjected to SDS-PAGE and transferred to a 
PVDF membrane. Specific signal was detected by Western blot analysis using a specific antibody against B2M or β-actin. c, d The graphs show the 
quantitative analysis of the gels from OVCAR-3 and SK-OV-3 cells, respectively, after densitometry (both n = 3). β-actin was served as a loading con-
trol. *P < 0.05. Phospho-Smad2 (p-Smad2) and total Smad2 were used as indicators for the TGF-β signaling pathway existed in those cells. p-Smad2 
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Fig. 5 Measurement of B2M concentration after TGF-β1 treatment. 
The concentration of B2M in the cytosol and culture medium of 
OVCAR-3 and SK-OV-3 cells in the absence (−) or presence (+) of 
10 ng/ml TGF-β1 for 72 h (a) and 24 and 48 h (b), respectively, was 
determined by the ELISA assay. *P < 0.05
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The highest expression of B2M was found in patients 
with borderline and malignant tumours compared with 
women with normal ovary, suggesting that the overex-
pression of B2M may be associated with aggressive dis-
ease. Current study did not test the serum level of B2M 
due to the lack of serum collection before or after sur-
gery, but previous study has shown that the serum and 
peritoneal fluid of B2M was significant higher in patients 
with OC than in patients with benign neoplasms [27]. 
Our further analysis of B2M expression in different his-
topathological types of ovarian tumours showed that 
B2M protein expression was not associated with clinical 
features, such as age, tumour size, multifocal tumours, 
lymph node metastasis and clinical stage. Although the 
number of cases in this study is relatively small (total 108 
patients with ovarian tumour), our findings are similar to 
the results obtained from a breast cancer study that the 






































































































































Fig. 6 Regulation of the expression of B2M at mRNA and protein levels by the TGF-β signaling pathway in ovarian cancer cell lines. OVCAR-3 and 
SK-OV-3 cells were pre-treated with a TGF-β type I receptor kinases inhibitor (SB431542, 10 μM) for 30 min and then treated with 10 ng/ml TGF-β1. 
B2M mRNA in OVCAR-3 (a) and SK-OV-3 (b) cells was detected by quantitative RT-PCR using primers specific to B2M after TGF-β1 treatment for 24 h. 
B2M protein in OVCAR-3 (c) and SK-OV-3 (d) cells was detected by Western blot analysis using a specific antibody against B2M and β-actin after TGF-
β1 treatment for 72 and 48 h, respectively. Histograms show the quantitative analysis of the gels after densitometry. The results are representative of 
three independent experiments. *P < 0.05
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lymph node metastasis and clinical stage [29]. However 
in patients with gallbladder cancer, B2M expression is 
significantly correlated with large tumour size, high TNM 
stage, lymph node metastasis and invasion of carcino-
mas [30]. These data suggest that the association of B2M 
expression with clinical features is tumour-type specific. 
Nevertheless, our findings, coming together with recent 
evidences from other laboratories, support the notion 
that B2M is a potential marker for the diagnosis of OC, 
especially the epithelial-type borderline and malignant 
tumours of the ovary.
It has been shown that the overexpression of B2M pro-
motes SK-OV-3 cell proliferation and an antibody against 
B2M inhibits proliferation and induces apoptosis [31]. 
Besides, B2M is also involved in promoting lethal bone 
and soft tissue metastases in host mice [32]. Our in vitro 
studies demonstrate that knocking down of B2M leads to 
the decrease of OC cell growth, as well as their migration 
and invasion, indicating that B2M has a cellular function 
in regulating cell behaviors, such as cell proliferation, 
migration and invasion. These data suggest that B2M 
may play an important role in the development of OC.
Ovarian tumorigenesis is mediated by various signal-
ing pathways, including the TGF-β signaling pathway. Our 
recent study has shown that TGF-β1 regulates cystatin B, 
a progression marker of human epithelial ovarian tumour, 
in OC cells [25]. Studies from other groups also show that 
TGF-β modulates serous borderline ovarian tumour inva-
sion [23] and increased the metastatic potential of OC 
cells [24]. However, whether the TGF-β signaling pathway 
involved in B2M regulation remains unknown. The cur-
rent study examined for the first time that TGF-β1 medi-
ates B2M expression at mRNA and protein levels in OC 
cells. A downregulation of B2M expression was observed 
after TGF-β1 treatment in OVCAR-3 and SK-OV-3 cells. 
The inhibition of TGF-β signaling by its type I receptor 
inhibitor abolished the downregulation of B2M, indicat-
ing that the expression of B2M is indeed regulated by the 
TGF-β signaling pathway. However, how TGF-β regulates 
B2M expression in vivo is not completely understood. The 
data from public database NCBI GEO DataSets reveal that 
TGF-β1 did not affect B2M expression within 12  h in an 
immortalized ovarian surface epithelial (IOSE) cell line in a 
time-course study as there is no direct evidence showing a 
Smad specific target promoter in B2M gene [33]. We found 
that TGF-β1-mediated B2M expression needs at least 24 h, 
indicating that TGF-β1 regulates B2M expression via other 
mechanisms. The dysregulation of TGF-β signaling during 
OC development [34, 35] may lead to the upregulation of 
B2M expression. Indeed, the alteration of TGF-β compo-
nents is found in human OC [36–39]. Further study in an 
animal model of OC is needed to examine the molecular 
mechanism underlying TGF-β-mediated B2M expression.
Because B2M is non-covalently linked to the α heavy 
chain of MHC class I complex and the loss of MHC class I 
molecules is one of the mechanisms for tumours to escape 
the recognition and destruction of immune system, the 
dysregulation of B2M between the membrane and soluble 
forms may play a role in ovarian tumorigenesis. Although 
we detected a reduction of cytosolic B2M by TGF-β1, the 
level of B2M in the culture medium was not significantly 
changed due to the larger volume compared to the cyto-
solic volume. Previous studies have shown that OC cell 
lines express MHC class I molecules as well as immuno-
suppressive TGF-β1 mRNA and protein which was only 
modestly detected in cell culture supernatants [40, 41]. 
The poor secretion of TGF-β1 in tumour cells may result 
in low autocrine and exocrine of this cytokine and finally 
lead to the induction of B2M expression. The current study 
examined the expression of B2M in ovarian tumours, but 
whether B2M is involved in tumour cell immune-escape in 
addition to immunosurveillance in patients with OC will 
need to be evaluated in subsequent studies.
Conclusions
B2M was overexpressed in human epithelial-type bor-
derline and malignant tumours of the ovary. B2M acted 
as a positive regulator in the proliferation, migration and 
invasion of OC cells and was regulated at mRNA and 
protein levels by the TGF-β signaling pathway, indicating 
a possible role of B2M in ovarian tumorigenesis. Target-
ing B2M, such as using siRNA, may provide a potential 
therapeutic application for patients with B2M-overex-
pressing ovarian tumour.
Abbreviations
B2M: beta-2 microglobulin; ELISA: enzyme-linked immunosorbent assay; EOC: 
epithelial ovarian cancer; IHC: immunohistochemistry; MHC: major histocom-
patibility complex; OC: ovarian cancer; TGF-β: transforming growth factor-β.
Authors’ contributions
WS conducted experiments, data analyses, and figure and manuscript prepa-
ration. LG contributed to the project development and pathological diagnosis. 
XZ collected the clinical samples and confirmed the diagnosis. LZ and DZ 
performed the experiments. XD contributed to patient collection and clinical 
data interpretation. WR contributed to the tissue collection and pathologi-
cal diagnosis. GX contributed to the experiment design, data analysis, figure 
generation and manuscript writing. All authors read and approved the final 
manuscript.
Author details
1 Center Laboratory, Jinshan Hospital, Fudan University, 1508 Longhang Road, 
Shanghai 201508, People’s Republic of China. 2 Department of Pathology, 
Jinshan Hospital, Fudan University, Shanghai 201508, China. 3 Department 
of Obstetrics and Gynecology, Jinshan Hospital, Fudan University, Shang-
hai 201508, China. 4 Department of Oncology, Shanghai Medical College, 
Fudan University, Shanghai 200032, China. 
Acknowledgements
This work was supported by grants from National Natural Science Foundation 
of China (81272880), the Shanghai Committee of Science and Technology 
(124119b1300), and Shanghai Municipal Health Bureau (20124186) to GX.
Page 12 of 13Sun et al. J Transl Med  (2016) 14:75 
Competing interests
The authors declare that they have no competing interests.
Received: 15 January 2016   Accepted: 7 March 2016
References
 1. Melillo L, Musto P, Tomasi P, Cascavilla N, Bodenizza C, Ladogana S, et al. 
Serum beta 2-microglobulin in malignant lymphoproliferative disorders. 
Tumori. 1988;74(2):129–35.
 2. Gussow D, Rein R, Ginjaar I, Hochstenbach F, Seemann G, Kottman A, et al. 
The human beta 2-microglobulin gene. Primary structure and definition 
of the transcriptional unit. J Immunol. 1987;139(9):3132–8.
 3. Liabeuf A, le de Kaouel Borgne C, Kourilsky FM, Malissen B, Manuel Y, 
Sanderson AR. An antigenic determinant of human beta 2-microglobulin 
masked by the association with HLA heavy chains at the cell surface: 
analysis using monoclonal antibodies. J Immunol. 1981;127(4):1542–8.
 4. Klein B, Levin I, Lurie H, Nyska A, Shapira J, Kravits M, et al. Elevated pre-
treatment levels of soluble CD8 and Beta-2-microglobulin as indicators of 
relapse in breast-cancer patients. Int J Oncol. 1994;4(2):471–4.
 5. Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, et al. 
Beta(2)microglobulin mRNA expression levels are prognostic for 
lymph node metastasis in colorectal cancer patients. Br J Cancer. 
2008;98(12):1999–2005. doi:10.1038/sj.bjc.6604399.
 6. Sasaki T, Ravindranath MH, Terasaki PI, Freitas MC, Kawakita S, Jucaud V. 
Gastric cancer progression may involve a shift in HLA-E profile from an 
intact heterodimer to beta2-microglobulin-free monomer. Int J Cancer. 
2014;134(7):1558–70. doi:10.1002/ijc.28484.
 7. Charalabopoulos K, Papalimneou V, Charalabopoulos A, Zoganas L, 
Andronadi V, Stefanou D, et al. Serum estimation of carcinoembryonic 
antigen, beta(2)-microglobulin and calcitonin as tumor markers in 
primary lung cancer. J BUON. 2003;8(1):35–7.
 8. Manzar W, Raghavan MR, Aroor AR, Keshavamurthy KR. Evaluation of 
serum beta 2-microglobulin in oral cancer. Aust Dent J. 1992;37(1):39–42.
 9. Khoo SK, Daunter B, Mackay E. Carcinoembryonic antigen and beta 
2-microglobulin as serum tumor markers in women with genital cancer. 
Int J Gynaecol Obstet. 1979;16(5):388–93.
 10. Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, et al. Beta-2-microglobulin 
is an androgen-regulated secreted protein elevated in serum of patients 
with advanced prostate cancer. Clin Cancer Res. 2007;13(7):1979–86. 
doi:10.1158/1078-0432.CCR-06-1156.
 11. Johnson H Jr, Flye MW, Javadpour N. Serum beta 2 microglobulin levels in 
patients with testicular cancer. Urology. 1980;16(5):522–4.
 12. Pokrass MJ, Liu MF, Lindorfer MA, Taylor RP. Activation of complement by 
monoclonal antibodies that target cell-associated beta(2)-microglobulin: 
implications for cancer immunotherapy. Mol Immunol. 2013;56(4):549–
60. doi:10.1016/j.molimm.2013.05.242.
 13. Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LW. Beta2-
Microglobulin-mediated signaling as a target for cancer therapy. Antican-
cer Agents Med Chem. 2014;14(3):343–52.
 14. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Mendez R, Gonzalez-
Aseguinolaza G, et al. Immune escape of cancer cells with beta2-
microglobulin loss over the course of metastatic melanoma. Int J Cancer. 
2014;134(1):102–13. doi:10.1002/ijc.28338.
 15. Bossard C, Bezieau S, Matysiak-Budnik T, Volteau C, Laboisse CL, Jotereau 
F, et al. HLA-E/beta2 microglobulin overexpression in colorectal cancer 
is associated with recruitment of inhibitory immune cells and tumor 
progression. Int J Cancer. 2012;131(4):855–63. doi:10.1002/ijc.26453.
 16. Nomura T, Huang WC, Zhau HE, Wu D, Xie Z, Mimata H, et al. Beta2-
microglobulin promotes the growth of human renal cell carcinoma 
through the activation of the protein kinase A, cyclic AMP-responsive 
element-binding protein, and vascular endothelial growth factor axis. Clin 
Cancer Res. 2006;12(24):7294–305. doi:10.1158/1078-0432.CCR-06-2060.
 17. Rowley DR, Dang TD, McBride L, Gerdes MJ, Lu B, Larsen M. Beta-2 
microglobulin is mitogenic to PC-3 prostatic carcinoma cells and 
antagonistic to transforming growth factor beta 1 action. Cancer Res. 
1995;55(4):781–6.
 18. Massague J, Wotton D. Transcriptional control by the TGF-beta/
Smad signaling system. EMBO J. 2000;19(8):1745–54. doi:10.1093/
emboj/19.8.1745.
 19. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major 
Smad pathways in TGF-beta superfamily signalling. Genes Cells. 
2002;7(12):1191–204.
 20. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor 
beta in human disease. N Engl J Med. 2000;342(18):1350–8. doi:10.1056/
NEJM200005043421807.
 21. Prat J, Franceschi S. Cancers of the female reproductive organs. In: Stew-
art BW, Wild CP, editors. World Cancer Report 2014. Lyon: International 
Agency for Research on Cancer; 2014. p. 660–83.
 22. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-
beta modulates ovarian cancer invasion by upregulating CAF-derived 
versican in the tumor microenvironment. Cancer Res. 2013;73(16):5016–
28. doi:10.1158/0008-5472.CAN-13-0023.
 23. Cheng JC, Auersperg N, Leung PC. TGF-beta induces serous borderline 
ovarian tumor cell invasion by activating EMT but triggers apoptosis in 
low-grade serous ovarian carcinoma cells. PLoS One. 2012;7(8):e42436. 
doi:10.1371/journal.pone.0042436.
 24. Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK. 
Transforming growth factor-beta-induced protein secreted by peritoneal 
cells increases the metastatic potential of ovarian cancer cells. Int J Can-
cer. 2011;128(7):1570–84. doi:10.1002/ijc.25494.
 25. Wang X, Gui L, Zhang Y, Zhang J, Shi J, Xu G. Cystatin B is a progression 
marker of human epithelial ovarian tumors mediated by the TGF-beta 
signaling pathway. Int J Oncol. 2014;44(4):1099–106. doi:10.3892/
ijo.2014.2261.
 26. Lee YH, Kim JH, Zhou H, Kim BW, Wong DT. Salivary transcriptomic bio-
markers for detection of ovarian cancer: for serous papillary adenocarci-
noma. J Mol Med. 2012;90(4):427–34. doi:10.1007/s00109-011-0829-0.
 27. Kucukgoz Gulec U, Paydas S, Guzel AB, Buyukkurt S, Seydaoglu G, Vardar 
MA, et al. Comparative analysis of CA 125, ferritin, beta-2 microglobulin, 
lactic dehydrogenase levels in serum and peritoneal fluid in patients 
with ovarian neoplasia. Med Oncol. 2012;29(4):2937–43. doi:10.1007/
s12032-012-0165-4.
 28. Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, 
et al. Gene expression profiling supports the hypothesis that human 
ovarian surface epithelia are multipotent and capable of serving 
as ovarian cancer initiating cells. BMC Med Genomics. 2009;2:71. 
doi:10.1186/1755-8794-2-71.
 29. Li K, Du H, Lian X, Yang S, Chai D, Wang C, et al. Characterization of beta2-
microglobulin expression in different types of breast cancer. BMC Cancer. 
2014;14:750. doi:10.1186/1471-2407-14-750.
 30. Sun J, Yang ZL, Miao X, Zou Q, Li J, Liang L, et al. ATP5b and beta2-
microglobulin are predictive markers for the prognosis of patients 
with gallbladder cancer. J Mol Histol. 2015;46(1):57–65. doi:10.1007/
s10735-014-9597-9.
 31. Yang HS, Li Y, Deng HX, Peng F. Identification of beta2-microglobulin as a 
potential target for ovarian cancer. Cancer Biol Ther. 2009;8(24):2323–8.
 32. Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, et al. Beta2-
microglobulin induces epithelial to mesenchymal transition and confers 
cancer lethality and bone metastasis in human cancer cells. Cancer Res. 
2011;71(7):2600–10. doi:10.1158/0008-5472.CAN-10-3382.
 33. Qin H, Chan MW, Liyanarachchi S, Balch C, Potter D, Souriraj IJ, 
et al. An integrative ChIP-chip and gene expression profiling 
to model SMAD regulatory modules. BMC Syst Biol. 2009;3:73. 
doi:10.1186/1752-0509-3-73.
 34. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, et al. 
Regulation of growth of normal ovarian epithelial cells and ovarian can-
cer cell lines by transforming growth factor-beta. Am J Obstet Gynecol. 
1992;166(2):676–84.
 35. Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian 
surface epithelium. J Obstet Gynaecol Res. 2007;33(1):3–16.
 36. Cardillo MR, Yap E, Castagna G. Molecular genetic analysis of TGF-beta1 in 
ovarian neoplasia. J Exp Clin Cancer Res. 1997;16(1):49–56.
 37. Wang D, Kanuma T, Mizunuma H, Takama F, Ibuki Y, Wake N, et al. Analysis 
of specific gene mutations in the transforming growth factor-beta 
signal transduction pathway in human ovarian cancer. Cancer Res. 
2000;60(16):4507–12.
Page 13 of 13Sun et al. J Transl Med  (2016) 14:75 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 38. Chen T, Triplett J, Dehner B, Hurst B, Colligan B, Pemberton J, et al. Trans-
forming growth factor-beta receptor type I gene is frequently mutated in 
ovarian carcinomas. Cancer Res. 2001;61(12):4679–82.
 39. Lynch MA, Nakashima R, Song H, DeGroff VL, Wang D, Enomoto T, 
et al. Mutational analysis of the transforming growth factor beta 
receptor type II gene in human ovarian carcinoma. Cancer Res. 
1998;58(19):4227–32.
 40. Toutirais O, Chartier P, Dubois D, Bouet F, Leveque J, Catros-Quemener V, 
et al. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 
by tumor cells as a major component of immune escape in human ovar-
ian carcinoma. Eur Cytokine Netw. 2003;14(4):246–55.
 41. Carr TM, Adair SJ, Fink MJ, Hogan KT. Immunological profiling of a panel 
of human ovarian cancer cell lines. Cancer Immunol Immunother. 
2008;57(1):31–42. doi:10.1007/s00262-007-0347-7.
